当前位置: 首页 >> 检索结果
3581. Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators.
作者: Nguyen Dinh Van.;Christine S Falk.;Lisa Sandmann.;Florian W R Vondran.;Fabian Helfritz.;Heiner Wedemeyer.;Michael P Manns.;Sandra Ciesek.;Thomas von Hahn.
来源: Gut. 2016年65卷6期1015-23页
In HCV infected individuals graft infection occurs shortly after orthotopic liver transplantation (OLT). We aimed to describe the composition of the inflammatory response at this time, how it affects the HCV replication cycle and identify novel proviral and antiviral factors.
3582. miR-30-HNF4γ and miR-194-NR2F2 regulatory networks contribute to the upregulation of metaplasia markers in the stomach.
作者: Josane F Sousa.;Ki Taek Nam.;Christine P Petersen.;Hyuk-Joon Lee.;Han-Kwang Yang.;Woo Ho Kim.;James R Goldenring.
来源: Gut. 2016年65卷6期914-24页
Intestinal metaplasia and spasmolytic polypeptide-expressing metaplasia (SPEM) are considered neoplastic precursors of gastric adenocarcinoma and are both marked by gene expression alterations in comparison to normal stomach. Since miRNAs are important regulators of gene expression, we sought to investigate the role of miRNAs on the development of stomach metaplasias.
3583. Antitumour activity of an inhibitor of miR-34a in liver cancer with β-catenin-mutations.
作者: Angélique Gougelet.;Chiara Sartor.;Laura Bachelot.;Cécile Godard.;Carmen Marchiol.;Gilles Renault.;Frédéric Tores.;Patrick Nitschke.;Catherine Cavard.;Benoit Terris.;Christine Perret.;Sabine Colnot.
来源: Gut. 2016年65卷6期1024-34页
Hepatocellular carcinoma (HCC) is the most prevalent primary tumour of the liver. About a third of these tumours presents activating mutations of the β-catenin gene. The molecular pathogenesis of HCC has been elucidated, but mortality remains high, and new therapeutic approaches, including treatments based on microRNAs, are required. We aimed to identify candidate microRNAs, regulated by β-catenin, potentially involved in liver tumorigenesis.
3584. A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis.
作者: Stephan Miehlke.;Petr Hruz.;Michael Vieth.;Christian Bussmann.;Ulrike von Arnim.;Monther Bajbouj.;Christoph Schlag.;Ahmed Madisch.;Christiane Fibbe.;Henning Wittenburg.;Hans Dieter Allescher.;Max Reinshagen.;Stefan Schubert.;Jan Tack.;Michaela Müller.;Patrick Krummenerl.;Joris Arts.;Ralph Mueller.;Karin Dilger.;Roland Greinwald.;Alex Straumann.
来源: Gut. 2016年65卷3期390-9页
To investigate the efficacy and safety of two different budesonide formulations (effervescent tablet for orodispersible use (BET) and viscous suspension (BVS)) with different daily dosages for short-term treatment of eosinophilic oesophagitis (EoE).
3585. An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis.
作者: Patrick M Lynch.;Carol A Burke.;Robin Phillips.;Jeffrey S Morris.;Rebecca Slack.;Xuemei Wang.;Jun Liu.;Sherri Patterson.;Frank A Sinicrope.;Miguel A Rodriguez-Bigas.;Elizabeth Half.;Steffen Bulow.;Andrew Latchford.;Sue Clark.;William A Ross.;Bonnie Malone.;Hennie Hasson.;Ellen Richmond.;Ernest Hawk.
来源: Gut. 2016年65卷2期286-95页
Although Non-steroidal anti-inflammatory drugs reduce colorectal adenoma burden in familial adenomatous polyposis (FAP), the utility of combining chemopreventive agents in FAP is not known. We conducted a randomised trial of celecoxib (CXB) versus CXB+diflouromethylornithine (DFMO) to determine the synergistic effect, if any.
3586. Gastric tumour-derived ANGPT2 regulation by DARPP-32 promotes angiogenesis.
作者: Zheng Chen.;Shoumin Zhu.;Jun Hong.;Mohammed Soutto.;DunFa Peng.;Abbes Belkhiri.;Zekuan Xu.;Wael El-Rifai.
来源: Gut. 2016年65卷6期925-34页
Overexpression of dopamine and cAMP-regulated phosphoprotein, Mr 32000 (DARPP-32), and its truncated isoform (t-DARPP) are associated with gastric tumorigenesis. Herein, we investigated the role of DARPP-32 proteins in regulating angiopoietin 2 (ANGPT2) and promoting tumour angiogenesis.
3587. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis.
作者: Jennifer M Yeh.;Chin Hur.;Zachary Ward.;Deborah Schrag.;Sue J Goldie.
来源: Gut. 2016年65卷4期563-74页
To estimate the cost-effectiveness of noncardia gastric adenocarcinoma (NCGA) screening strategies based on new biomarker and endoscopic technologies.
3588. A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D).
作者: Ching Lam.;Wei Tan.;Matthew Leighton.;Margaret Hastings.;Melanie Lingaya.;Yirga Falcone.;Xiaoying Zhou.;Luting Xu.;Peter Whorwell.;Andrew F Walls.;Abed Zaitoun.;Alan Montgomery.;Robin Spiller.
来源: Gut. 2016年65卷1期91-9页
Immune activation has been reported in the mucosa of IBS patients with diarrhoea (IBS-D), and some small studies have suggested that mesalazine may reduce symptoms. We performed a double-blind, randomised placebo-controlled trial of 2 g mesalazine twice daily versus placebo for 3 months in patients with Rome III criteria IBS-D. Primary outcome was daily average stool frequency during weeks 11-12; secondary outcomes were abdominal pain, stool consistency, urgency and satisfactory relief of IBS symptoms.
3589. Diagnostic accuracy study of anorectal manometry for diagnosis of dyssynergic defecation.
作者: Ugo Grossi.;Emma V Carrington.;Adil E Bharucha.;Emma J Horrocks.;S Mark Scott.;Charles H Knowles.
来源: Gut. 2016年65卷3期447-55页
The diagnostic accuracy of anorectal manometry (AM), which is necessary to diagnose functional defecatory disorders (FDD), is unknown. Using blinded analysis and standardised reporting of diagnostic accuracy, we evaluated whether AM could discriminate between asymptomatic controls and patients with functional constipation (FC).
3590. TLR-independent anti-inflammatory function of intestinal epithelial TRAF6 signalling prevents DSS-induced colitis in mice.
作者: Katerina Vlantis.;Apostolos Polykratis.;Patrick-Simon Welz.;Geert van Loo.;Manolis Pasparakis.;Andy Wullaert.
来源: Gut. 2016年65卷6期935-43页
The gut microbiota modulates host susceptibility to intestinal inflammation, but the cell types and the signalling pathways orchestrating this bacterial regulation of intestinal homeostasis remain poorly understood. Here, we investigated the function of intestinal epithelial toll-like receptor (TLR) responses in the dextran sodium sulfate (DSS)-induced mouse model of colitis.
3591. Development and validation of the WASP classification system for optical diagnosis of adenomas, hyperplastic polyps and sessile serrated adenomas/polyps.
作者: Joep E G IJspeert.;Barbara A J Bastiaansen.;Monique E van Leerdam.;Gerrit A Meijer.;Susanne van Eeden.;Silvia Sanduleanu.;Erik J Schoon.;Tanya M Bisseling.;Manon Cw Spaander.;Niels van Lelyveld.;Marloes Bargeman.;Junfeng Wang.;Evelien Dekker.; .
来源: Gut. 2016年65卷6期963-70页
Accurate endoscopic differentiation would enable to resect and discard small and diminutive colonic lesions, thereby increasing cost-efficiency. Current classification systems based on narrow band imaging (NBI), however, do not include neoplastic sessile serrated adenomas/polyps (SSA/Ps). We aimed to develop and validate a new classification system for endoscopic differentiation of adenomas, hyperplastic polyps and SSA/Ps <10 mm.
3592. Population-based assessment of the outcomes in patients with postcolonoscopy colorectal cancers.
作者: Anand Govindarajan.;Linda Rabeneck.;Lingsong Yun.;Jill Tinmouth.;Lawrence F Paszat.;Nancy N Baxter.
来源: Gut. 2016年65卷6期971-6页
The potential for cancers to not be detected on colonoscopy is increasingly recognised, but little is known about patient outcomes. The objective of this study was to assess the outcomes of patients diagnosed with postcolonoscopy colorectal cancers (PCCRCs).
3593. Multimodality endoscopic eradication for neoplastic Barrett oesophagus: results of an European multicentre study (EURO-II).
作者: K Nadine Phoa.;Roos E Pouw.;Raf Bisschops.;Oliver Pech.;Krish Ragunath.;Bas L A M Weusten.;Brigitte Schumacher.;Bjorn Rembacken.;Alexander Meining.;Helmut Messmann.;Erik J Schoon.;Liebwin Gossner.;Jayan Mannath.;C A Seldenrijk.;Mike Visser.;Toni Lerut.;Stefan Seewald.;Fiebo J ten Kate.;Christian Ell.;Horst Neuhaus.;Jacques J G H M Bergman.
来源: Gut. 2016年65卷4期555-62页
Focal endoscopic resection (ER) followed by radiofrequency ablation (RFA) safely and effectively eradicates Barrett's oesophagus (BO) containing high-grade dysplasia (HGD) and/or early cancer (EC) in smaller studies with limited follow-up. Herein, we report long-term outcomes of combined ER and RFA for BO (HGD and/or EC) from a single-arm multicentre interventional study.
3594. Deep resequencing of 131 Crohn's disease associated genes in pooled DNA confirmed three reported variants and identified eight novel variants.
作者: Sung Noh Hong.;Changho Park.;Soo Jung Park.;Chang Kyun Lee.;Byong Duk Ye.;You Sun Kim.;Seungbok Lee.;Jeesoo Chae.;Jong-Il Kim.;Young-Ho Kim.; .
来源: Gut. 2016年65卷5期788-96页
Genome wide association studies (GWAS) and meta-analyses for Crohn's disease (CD) have not fully explained the heritability of CD, suggesting that additional loci are yet to be found and that the known loci may contain high effect rare risk variants that have thus far gone undetected by GWAS. While the cost of deep sequencing remains too high to analyse many samples, targeted sequencing of pooled DNA samples allows the efficient and cost effective capture of all variations in a target region.
3595. Clinical and endoscopic predictors of cytological dysplasia or cancer in a prospective multicentre study of large sessile serrated adenomas/polyps.
作者: Nicholas G Burgess.;Maria Pellise.;Kavinderjit S Nanda.;Luke F Hourigan.;Simon A Zanati.;Gregor J Brown.;Rajvinder Singh.;Stephen J Williams.;Spiro C Raftopoulos.;Donald Ormonde.;Alan Moss.;Karen Byth.;Heok P'Ng.;Duncan McLeod.;Michael J Bourke.
来源: Gut. 2016年65卷3期437-46页
The serrated neoplasia pathway accounts for up to 30% of all sporadic colorectal cancers (CRCs). Sessile serrated adenomas/polyps (SSA/Ps) with cytological dysplasia (SSA/P-D) are a high-risk serrated CRC precursor with little existing data. We aimed to describe the clinical and endoscopic predictors of SSA/P-D and high grade dysplasia (HGD) or cancer.
3596. Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease.
作者: James B Canavan.;Cristiano Scottà.;Anna Vossenkämper.;Rimma Goldberg.;Matthew J Elder.;Irit Shoval.;Ellen Marks.;Emilie Stolarczyk.;Jonathan W Lo.;Nick Powell.;Henrieta Fazekasova.;Peter M Irving.;Jeremy D Sanderson.;Jane K Howard.;Simcha Yagel.;Behdad Afzali.;Thomas T MacDonald.;Maria P Hernandez-Fuentes.;Nahum Y Shpigel.;Giovanna Lombardi.;Graham M Lord.
来源: Gut. 2016年65卷4期584-94页
Thymus-derived regulatory T cells (Tregs) mediate dominant peripheral tolerance and treat experimental colitis. Tregs can be expanded from patient blood and were safely used in recent phase 1 studies in graft versus host disease and type 1 diabetes. Treg cell therapy is also conceptually attractive for Crohn's disease (CD). However, barriers exist to this approach. The stability of Tregs expanded from Crohn's blood is unknown. The potential for adoptively transferred Tregs to express interleukin-17 and exacerbate Crohn's lesions is of concern. Mucosal T cells are resistant to Treg-mediated suppression in active CD. The capacity for expanded Tregs to home to gut and lymphoid tissue is unknown.
3597. Efficacy and safety of endoscopic resection of large colorectal polyps: a systematic review and meta-analysis.
作者: C Hassan.;A Repici.;P Sharma.;L Correale.;A Zullo.;M Bretthauer.;C Senore.;C Spada.;Cristina Bellisario.;P Bhandari.;D K Rex.
来源: Gut. 2016年65卷5期806-20页
To assess the efficacy and safety of endoscopic resection of large colorectal polyps.
3598. Decreased miR-199 augments visceral pain in patients with IBS through translational upregulation of TRPV1.
作者: QiQi Zhou.;Liuqing Yang.;Scott Larson.;Sapreet Basra.;Shehzad Merwat.;Alai Tan.;Carlo Croce.;G Nicholas Verne.
来源: Gut. 2016年65卷5期797-805页
Many patients with irritable bowel syndrome IBS not only have abdominal pain but also may suffer from visceral hypersensitivity and heighted visceral nociception. Moreover, IBS has few effective therapeutic agents and mechanisms of disease are unclear. Our goals were to (i) identify microRNA (miRNA) expression, signalling and targets in human colon (controls; patients with IBS); (ii) verify in vitro, IBS-associated changes in miRNAs, especially miR-199, which is complementary to the transient receptor potential vanilloid type 1 (TRPV1) gene; and (iii) determine whether modulating the expression of miRNAs in vivo, especially miR-199, reverses associated changes and pathological hallmarks of visceral hypersensitivity via TRPV1 signalling.
3599. Ceramide-CD300f binding suppresses experimental colitis by inhibiting ATP-mediated mast cell activation.
作者: Toshihiro Matsukawa.;Kumi Izawa.;Masamichi Isobe.;Mariko Takahashi.;Akie Maehara.;Yoshinori Yamanishi.;Ayako Kaitani.;Ko Okumura.;Takanori Teshima.;Toshio Kitamura.;Jiro Kitaura.
来源: Gut. 2016年65卷5期777-87页
Extracellular ATP mediates mast cell-dependent intestinal inflammation via P2X7 purinoceptors. We have previously shown that CD300f (also called the leucocyte mono-immunoglobulin-like receptor 3 (LMIR3)) suppresses immunoglobulin E-dependent and mast cell-dependent allergic responses by binding to ceramide. The aim of the present study was to clarify the role of ceramide-LMIR3 interaction in the development of IBD.
3600. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study.
作者: Andres J Yarur.;Anjali Jain.;Daniel A Sussman.;Jamie S Barkin.;Maria A Quintero.;Fred Princen.;Richard Kirkland.;Amar R Deshpande.;Sharat Singh.;Maria T Abreu.
来源: Gut. 2016年65卷2期249-55页
The aim of this study was to assess the correlation between serum and intestinal anti-tumour necrosis factor (TNF) levels, and their relationship to endoscopic disease activity and levels of TNF.
|